Background SARS-CoV-2, the virus that caused the global COVID-19 pandemic, has severely impacted Central Asia; in spring 2020, high numbers of cases and deaths were reported in this region. The second wave of the COVID-19 pandemic is currently breaching the borders of Central Asia. Public health surveillance is necessary to inform policy and guide leaders; however, existing surveillance explains past transmissions while obscuring shifts in the pandemic, increases in infection rates, and the persistence of the transmission of COVID-19. Objective The goal of this study is to provide enhanced surveillance metrics for SARS-CoV-2 transmission that account for weekly shifts in the pandemic, including speed, acceleration, jerk, and persistence, to better understand the risk of explosive growth in each country and which countries are managing the pandemic successfully. Methods Using a longitudinal trend analysis study design, we extracted 60 days of COVID-19–related data from public health registries. We used an empirical difference equation to measure the daily number of cases in the Central Asia region as a function of the prior number of cases, level of testing, and weekly shift variables based on a dynamic panel model that was estimated using the generalized method of moments approach by implementing the Arellano-Bond estimator in R. Results COVID-19 transmission rates were tracked for the weeks of September 30 to October 6 and October 7-13, 2020, in Central Asia. The region averaged 11,730 new cases per day for the first week and 14,514 for the second week. Infection rates increased across the region from 4.74 per 100,000 persons to 5.66. Russia and Turkey had the highest 7-day moving averages in the region, with 9836 and 1469, respectively, for the week of October 6 and 12,501 and 1603, respectively, for the week of October 13. Russia has the fourth highest speed in the region and continues to have positive acceleration, driving the negative trend for the entire region as the largest country by population. Armenia is experiencing explosive growth of COVID-19; its infection rate of 13.73 for the week of October 6 quickly jumped to 25.19, the highest in the region, the following week. The region overall is experiencing increases in its 7-day moving average of new cases, infection, rate, and speed, with continued positive acceleration and no sign of a reversal in sight. Conclusions The rapidly evolving COVID-19 pandemic requires novel dynamic surveillance metrics in addition to static metrics to effectively analyze the pandemic trajectory and control spread. Policy makers need to know the magnitude of transmission rates, how quickly they are accelerating, and how previous cases are impacting current caseload due to a lag effect. These metrics applied to Central Asia suggest that the region is trending negatively, primarily due to minimal restrictions in Russia.
Lower extremity deep vein thrombosis (DVT) is frequently encountered in clinical practice. Postthrombotic syndrome (PTS) is a common sequela of DVT and encompasses a wide variety of symptoms, including severe pain, edema, and ulceration, all of which may contribute to a negative impact on quality of life. Studies have demonstrated that acute thrombosis of the iliofemoral venous segment is correlated with high rates of PTS, increased severity of symptoms, and high rates of thrombus recurrence, despite patients receiving treatment with standard-of-care anticoagulation therapy. Endovascular interventions, including catheter-directed thrombolysis, pharmacomechanical thrombectomy, and mechanical thrombectomy, have generated significant interest as a method for reduction of short-term symptom severity and potential reduction of downstream PTS severity. While there is high-quality evidence evaluating the role of catheter-directed and pharmacomechanical thrombectomy for acute iliofemoral DVT, newer mechanical-only devices that utilize thrombectomy without fibrinolytic medication are less studied. Currently, there are limited data evaluating the efficacy and safety of these treatment modalities, although investigations are ongoing.
BACKGROUND SARS-CoV-2, the virus that caused the COVID-19 global pandemic, has severely impacted Central Asia, resulting in a high caseload and deaths that varied by country in Spring 2020. The varying severity of the pandemic is explained by differences in prevention efforts in the form of public health policy, adherence to those guidelines, as well as socio-cultural, climate, and population characteristics. The second wave of the COVID-19 currently is breaching the borders of Europe. Public health surveillance is necessary to inform policy and guide leaders; however, existing surveillance explains past transmissions obscuring shifts in the pandemic, increases in infection rates, and the persistence in the transmission of COVID-19. OBJECTIVE The goal of this study is to provide enhanced surveillance metrics for COVID-19 transmission that account for shifts in the pandemic, week over week, speed, acceleration, jerk and persistence, to better understand country risk for explosive growth and those who are managing the pandemic successfully. Existing surveillance, coupled with our dynamic metrics of transmission, will inform health policy to control the COVID-19 pandemic until an effective vaccine is developed and provides novel metrics to measure the transmission of disease. METHODS Using a longitudinal trend analysis study design, we extracted 60 days of COVID data from public health registries. We use an empirical difference equation to measure the daily number of cases in the Central Asia region as a function of the prior number of cases, the level of testing, and weekly shift variables based on a dynamic panel model that was estimated using the generalized method of moments (GMM) approach by implementing the Arellano-Bond estimator in R. RESULTS COVID-19 transmission rates were tracked for the weeks of 9/30-10/06 and 10/07 to 10/13 in Central Asia. The region averaged 11,730 new cases per day for the week ending in 10/06 and 14,514 for the week ending in 10/13. Infection rates increased across the region from 4.74 per 100,000 in the population to 5.66. Infection rates varied by country. Russia and Turkey had the highest seven-day moving averages in the region, at 9,836 and 1,469 respectively for the week of 10/06 and 12,501 and 1,603 respectively for the week of 10/13. Russia has the fourth highest speed in the region and continues to have positive acceleration, driving the negative trend for the entire region as the largest country by population. Armenia is experiencing explosive growth of COVID-19, with an infection rate of 13.73 for the week of 10/06 quickly jumping to 25.19, the highest in the region, the following week. The pandemic speed in Armenia, consistent with the infection rate trajectory, increased from 15.4 to 21.7, with an acceleration increase from 0.4 to 1.6 meaning acceleration has increased fourfold. The region overall is experiencing increases in seven-day moving average of new cases, infection, rate and speed, with continued positive acceleration and no sign of a reversal in sight. CONCLUSIONS The rapidly evolving COVID-19 pandemic requires novel dynamic surveillance metrics in addition to static metrics to effectively analyze pandemic trajectory and control spread. Policymakers need to know the magnitude of transmission rates, how quickly they are accelerating, and how previous cases are impacting current caseload due to a lag effect. These metrics applied to Central Asia suggest that the region is trending negatively, primarily due to minimal restrictions in Russia. Russia already has the fourth highest number of cases in the world and current metrics suggest Russia will continue on that trajectory. CLINICALTRIAL NA
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.